Gilead Sciences Inc

NASDAQ: GILD
$92.76
-$1.59 (-1.7%)
Real Time Data Delayed 15 Min.

GILD Stock Chart and Intraday Price

GILD Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 333 LAKESIDE DR, FOSTER CITY, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 90,081.62M USD
Shares Outstanding 1,245,770,000
Gilead Sciences Inc is a leading biopharmaceutical company focused on developing and commercializing innovative medicines for life-threatening illnesses worldwide. With a strong emphasis on HIV/AIDS, COVID-19, viral hepatitis, and oncology, Gilead offers a range of treatments that address unmet medical needs. Notable products include Biktarvy, Veklury, and Yescarta. Founded in 1987 and based in Foster City, California, Gilead also engages in significant partnerships to advance its research and development efforts.

GILD Articles

These five blue chip dividend stocks would be ideal for investors who had to hold them forever, as they provide reliable streams of passive income.
24/7 Insights With the S&P 500 up 15% year-to-date, a correction could be coming in the third quarter. Stocks that pay dividends will be in big demand when interest rates start to fall over the...
24/7 Insights Quality dividend stocks outperform non-dividend stocks for shareholders. Dividend stocks can deliver dependable passive income streams. Access 2 legendary, high-yield dividend stocks...
24/7 Insights The Nasdaq is up a stunning 14.5% this year after a massive 43% gain in 2023. Nasdaq dividend stocks are still reasonably priced, including Cisco Systems Inc. (NASDAQ: CSCO). Unloved...
These seven stocks combined can generate about $3,750 a year in passive income for an investment of just $7,500 in each one.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third quarter running. Many top...
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the...
This year’s Artificial Intelligence rally led by the so-called “Magnificent 7” has been fantastic if you owned those stocks. The reality is the great bulk of the S&P 500 is treading water...
Here is a look at how shares of FuelCell Energy, Gilead Sciences, Starbucks and more have fared since their initial public offerings in 1992.
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and...
Monday's top analyst upgrades and downgrades included Adobe, Apple, Arch Capital, ChargePoint, CSX, Digital Ocean, First Solar, Gilead Sciences, Lucid, Shopify and Snowflake.
Private equity firms and institutions have been buying up top health care stocks like these seven for their strong total return potential and a degree of safety in what soon could be some very rough...
Monday's top analyst upgrades and downgrades included Amazon.com, Amgen, Apple, BioCryst Pharmaceuticals, Block, Coinbase Global, Datadog, Fortinet, Gilead Sciences, Intercontinental Exchange,...
When Nasdaq rebalances its Nasdaq 100 index, 7 top companies in the index will be upsized, and all are Buy rated across Wall Street.